Next Article in Journal
Primary Epithelioid Angiosarcoma of the Breast Masquerading as Carcinoma
Previous Article in Journal
Metastatic Lung Adenocarcinoma in a 20-Year-Old Patient
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 17
Issue 1
10.3747/co.v17i1.437
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Capecitabine-Induced Cardiotoxicity: Case Report and Review of the Literature

by
C. Ang
1,
M. Kornbluth
2,
M. P. Thirlwell
1 and
R. D. Rajan
1,*
1
Department of Oncology, McGill University Health Centre, Montreal, QC H3G 1A4, Canada
2
Department of Cardiology, McGill University Health Centre, Montreal, QC H3G 1A4, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2010, 17(1), 59-63; https://doi.org/10.3747/co.v17i1.437
Submission received: 7 November 2009 / Revised: 4 December 2009 / Accepted: 8 January 2010 / Published: 1 February 2010

Abstract

Capecitabine, an oral prodrug of 5-fluorouracil (5FU), has been integrated into the management of multiple cancer types because of convenience of administration and efficacy comparable with 5FU. Cardiotoxicity induced by 5FU—in particular angina—has been well described in the literature, but reports of adverse cardiac events with capecitabine are also emerging. The mechanism underlying 5FU cardiotoxicity has long been thought to result from coronary vasospasm, but animal-model studies and patient echocardiographic findings both suggest a cardiomyopathic picture. Although 5FU cardiotoxicity is often reversible and can be managed supportively, presentations that are more severe—including arrhythmias, acute ischemic events, and cardiogenic shock—have been documented. In this report, we describe the case of a patient who ultimately required a pacemaker after developing symptomatic bradycardia and sinus arrest while receiving capecitabine for colon cancer.
Keywords: 5-fluorouracil; capecitabine; cardiotoxicity; chemotherapy 5-fluorouracil; capecitabine; cardiotoxicity; chemotherapy

Share and Cite

MDPI and ACS Style

Ang, C.; Kornbluth, M.; Thirlwell, M.P.; Rajan, R.D. Capecitabine-Induced Cardiotoxicity: Case Report and Review of the Literature. Curr. Oncol. 2010, 17, 59-63. https://doi.org/10.3747/co.v17i1.437

AMA Style

Ang C, Kornbluth M, Thirlwell MP, Rajan RD. Capecitabine-Induced Cardiotoxicity: Case Report and Review of the Literature. Current Oncology. 2010; 17(1):59-63. https://doi.org/10.3747/co.v17i1.437

Chicago/Turabian Style

Ang, C., M. Kornbluth, M. P. Thirlwell, and R. D. Rajan. 2010. "Capecitabine-Induced Cardiotoxicity: Case Report and Review of the Literature" Current Oncology 17, no. 1: 59-63. https://doi.org/10.3747/co.v17i1.437

APA Style

Ang, C., Kornbluth, M., Thirlwell, M. P., & Rajan, R. D. (2010). Capecitabine-Induced Cardiotoxicity: Case Report and Review of the Literature. Current Oncology, 17(1), 59-63. https://doi.org/10.3747/co.v17i1.437

Article Metrics

Back to TopTop